In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The closing price of Zymeworks BC Inc (NASDAQ: ZYME) was $14.46 for the day, down -3.66% from the previous closing price of $15.01. In other words, the price has decreased by -$3.66 from its previous closing price. On the day, 0.75 million shares were traded. ZYME stock price reached its highest trading level at $15.25 during the session, while it also had its lowest trading level at $14.44.
Ratios:
Our analysis of ZYME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.10 and its Current Ratio is at 4.10. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On November 07, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $10 to $25.
Wells Fargo Downgraded its Overweight to Equal Weight on November 01, 2024, while the target price for the stock was maintained at $12.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’25 when Moore Paul Andrew sold 21,200 shares for $14.92 per share. The transaction valued at 316,391 led to the insider holds 14,741 shares of the business.
Galbraith Kenneth sold 57,291 shares of ZYME for $855,017 on Jan 06 ’25. The Chair & CEO now owns 47,543 shares after completing the transaction at $14.92 per share. On Jan 06 ’25, another insider, Smith Jeffrey T L, who serves as the EVP & Chief Medical Officer of the company, sold 11,110 shares for $14.92 each. As a result, the insider received 165,807 and left with 8,890 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZYME now has a Market Capitalization of 1033852416 and an Enterprise Value of 719047040. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.40 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at 11.56 whereas that against EBITDA is -6.269.
Stock Price History:
The Beta on a monthly basis for ZYME is 1.09, which has changed by 0.3052174 over the last 52 weeks, in comparison to a change of 0.24933672 over the same period for the S&P500. Over the past 52 weeks, ZYME has reached a high of $17.70, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is 0.58%, while the 200-Day Moving Average is calculated to be 27.98%.
Shares Statistics:
ZYME traded an average of 503.11K shares per day over the past three months and 624070 shares per day over the past ten days. A total of 69.58M shares are outstanding, with a floating share count of 66.65M. Insiders hold about 4.03% of the company’s shares, while institutions hold 99.90% stake in the company. Shares short for ZYME as of 1734048000 were 4338660 with a Short Ratio of 8.62, compared to 1731628800 on 4208640. Therefore, it implies a Short% of Shares Outstanding of 4338660 and a Short% of Float of 7.7700000000000005.
